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Since late ‘80s Avian metapneumovirus subtype A causes sufficient disease in Europe for 26 
commercial companies to have started developing live attenuated vaccines. Here, two of those 27 
vaccines were fully consensus sequenced alongside their progenitor field strain (#8544). Sequences 28 
comparison shows that the attenuation of field strain #8544 was associated with no common 29 
substitutions between the two derived vaccines. This finding suggests that the attenuation of field 30 
viruses via serial passage on cell cultures or tissues is the result of a random process, rather than a 31 
mechanism aiming to achieve a specific sequence. Furthermore, field vaccination strategies would 32 
greatly benefit by the unambiguous vaccine markers identified in this study, enabling a prompt and 33 
confident vaccines detection.  34 
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1. Introduction 36 
 37 
Avian metapneumovirus (AMPV) has caused disease and economic losses in unprotected 38 
commercial turkeys and chickens for at least four decades. In general the virus has been controlled 39 
by the preparation and use of highly effective live attenuated vaccines, made by random passage of 40 
a number of  AMPV field isolates in various cells or tissues [1,2]. In a small minority of 41 
circumstances, AMPV vaccines have been ineffective, and disease has sometimes been attributed to 42 
the use of vaccine subtype not matching the AMPV subtype in circulation [3]. On other occasions 43 
vaccine has been shown to cause disease by mutating back to a virulent state in the vaccinated birds, 44 
though fortuitous events and much background work was needed to prove this [4,5]. For some years, 45 
our laboratory has recognised the need for nucleic acid sequence markers for live attenuated poultry 46 
vaccines to enable vaccine tracking on farms. To that end, we have successfully identified several 47 
markers for live AMPV and infectious bronchitis virus (IBV) commercial vaccines and these in turn 48 
are now being used to monitor those viruses in commercial flocks internationally [4,6,7]. 49 
 50 
To be able to identify reliable sequence markers for a particular live attenuated vaccine, it is 51 
necessary to sequence both the vaccine and the field virus used in its preparation, ideally in their 52 
entirety. Comparison then reveals the mutations generated during the attenuation process. 53 
Regarding the approximately  fourteen kilobases AMPV genome, very roughly ten mutations have 54 
been found associated with the attenuation process [4,7], whereas for the roughly 28 kilobases IBV 55 
genome, the number of mutations is approximately doubled [6].  Finally, once mutations markers 56 
are identified, they are ideally compared to field strains present prior to a vaccine’s introduction, so 57 
as to eliminate the highly unlikely possibility that the same mutations might have been generated by 58 
other chance mechanisms.  59 
 60 
In the current study we report an unusual vaccine marker study whereby two commercial subtype A 61 
AMPV vaccines had been prepared from the identical progenitor field strain. In the late 1980s, 62 
AMPV (then named TRTV) was causing severe disease in the UK. Morbidity and mortality were 63 
crippling the turkey industry and there was an urgent need to produce protective vaccines. Very few 64 
virus isolates of this newly discovered virus were available and as a result a large UK based 65 
commercial turkey breeding company made their recently isolated field isolate #8544 [8,9] 66 
available to two different commercial vaccines producers. Both companies proceeded to attenuate 67 
the virus and release vaccines, both of which remain widely used throughout the world. Our group 68 
has previously described the generation of one of these vaccines [2,10] and is here named vaccine 1, 69 
but in the other case (vaccine 2), details of the attenuation procedure remains unreported. In this 70 
study, we have sequenced both vaccines in their entirety and compared them to determine vaccine 71 
markers. We have gone on to consider the implications of the marker patterns with respect to the 72 
justification of our vaccine marker approach, as well to consider the possible significance of the 73 
mutations discovered. 74 
 75 
2. Materials and methods 76 
 77 
2.1 Viruses 78 
Field virus #8544 was isolated in turkey embryo tracheal organ culture (TOC) from a field outbreak 79 
[9]. To produce vaccine 1, field isolate #8544 virus was attenuated by two passages in chick embryo 80 
liver cells then 20 passages in Vero cells. Vaccine 2 was produced from the same progenitor; while 81 
details of cells and tissues used have not been disclosed by the company concerned, Vero cells may 82 
also have been involved. Notably, prior master seed preparation (MSV), both the vaccines had been 83 
cloned by plaque purification following the attenuation passages on cells. 84 
 85 
 86 
2.2 Viral RNA extraction, RT-PCRs and sequencing 87 
Field virus  #8544, vaccine 1 and vaccine 2 were sequenced using the method previously reported 88 
[11]. Briefly, RNA was copied to full-length cDNA then amplified in three overlapping sections to 89 
cover the complete genome, then sequenced by Sanger sequencing using oligonucleotide primers 90 
matching known conserved regions. Where vaccines and progenitor consensus sequences differed, 91 
the locations were sequenced again, starting from newly isolated RNA. 92 
 93 
2.3 Sequences analysis and comparison 94 
Chromatograms were analysed using the program Chromas 95 
(http://technelysium.com.au/wp/chromas/) and sequences aligned using BioEdit 96 
(http://www.mbio.ncsu.edu/bioedit/bioedit.html). Open Reading Frame (ORF) prediction was 97 
carried out using ORFfinder program (https://www.ncbi.nlm.nih.gov/orffinder/). Predicted amino 98 
acids sequences were aligned using GeneRunner (http://www.generunner.net/). 99 
 100 
3. Results and discussion 101 
 102 
A comparison of virus sequences is depicted in table 1. Since their commercial release in the early 103 
1990s, both #8544 derived vaccines have been used to successfully protect many millions of 104 
chickens and turkeys on farms throughout the world. It is striking that despite the two vaccines do 105 
not share any of the same attenuating mutations, they showed, as reported in the two registration 106 
dossiers, a similar if not identical attenuated phenotype in vivo. Furthermore, after release of both 107 
vaccines, veterinarians in the UK and in continental Europe reported throughout the years their 108 
similar behaviour in the field. The attenuation of #8544 to produce vaccine 1 was associated with 109 
ten mutations, while vaccine 2 had seven mutations. Remarkably, none was the same. One broad 110 
sequence similarity was that for both vaccines, mutations within coding regions occurred between 111 
the F gene and the trailer end of the genome. For vaccine 1 genes altered were F, M2, G and L and 112 
for vaccine 2, F, SH and L. However, this similarity may be purely coincidental.  113 
 114 
A sometimes-cited criticism of use of nucleotide vaccine markers determined by progenitor/derived 115 
vaccine comparisons is that such identical mutations might arise randomly and spontaneously in the 116 
field. If truly random, simple calculation can show this possibility to be effectively zero. However, 117 
it might be hypothesised that certain specific field conditions select subpopulations sharing these 118 
same vaccine markers. While impossible to absolutely refute this possibility, the fact the two 119 
independent passages of #8544 did not produce any common mutations goes some way.  120 
Furthermore, we have never met an instance where detection of virus of apparent vaccine origin 121 
could not be associated with application of vaccine somewhere within the environment of potential 122 
spread. In our opinion, it is safe to conclude that any field virus found to contain two or three of the 123 
identified vaccine markers for a particular vaccine will have derived from that vaccine, whether 124 
having been applied on that farm of having spread to the farm via previous vaccinations at another 125 
location [5]. 126 
 127 
The coding mutation differences in each vaccine appear to show that the mechanisms of attenuation 128 
were different in each. For vaccine 2, three out of five coding mutations occurred in the L gene 129 
which codes for the viral polymerase. Interestingly our previous study concerning causes of 130 
reversion to virulence of vaccine 1 identified a single mutation in the L gene as responsible [12]. 131 
Thus, it is possible that attenuation of vaccine 2 was due to L gene changes. In contrast, the 132 
attenuation of #8544 to produce vaccine 1 in the first place involved no L mutation. Taking as a 133 
whole, this shows that mutations in a number of AMPV genome regions may lead to attenuation, 134 
rather than via a single mechanism.  135 
 136 
However, the coding fusion protein mutations found in vaccine 1 at nucleotide 3825 and in vaccine 137 
2 at nucleotide 3822 may be related. Both mutations occur within a region spanning amino acids  138 
293 to 296 of the fusion protein, whereby  the sequence of charged amino acids RKEK in #8544 are 139 
converted to RKKK in vaccine 1 and REEK in vaccine 2. Furthermore, during previously 140 
unreported commercial vaccine studies, we found two possibly related points of interest.  When 141 
vaccine 1 reverted to virulence in experimental conditions, RKKK mutated back to RKEK, 142 
although in association with other mutations. Secondly when reverse genetics was employed  to 143 
modify this region in a promising  candidate vaccine, it was found that in general virus viability 144 
required four charged amino acids in this region, though interestingly it could also be substituted by 145 
GGGG. Since that work other groups have reported the importance of amino acid 294 in inducing 146 
low pH membrane fusion in both avian and human metapneumovirus [13,14]. Hence, it is not 147 
impossible that this region was involved in the attenuation of both vaccines 1 and 2 and it should be 148 
considered a region worthy of further investigation. 149 
 150 
Vaccine 1 was produced primarily by passage of #8544 in Vero cells as previously reported [2]. 151 
Throughout the process, some of these passages were tested as vaccine candidates. Clearly, it would 152 
be of interest to go back and sequence those intermediate passages. However, because sequencing 153 
of vaccines 1 and 2 has taken place some considerable period after the production of vaccine 1 in 154 
the early 1990s, we no longer have access to those intermediates; hence, the possibility of 155 
correlating specific mutations to loss of virulence has unfortunately been lost. 156 
 157 
In conclusion, our study shows that production of similar empirical vaccines by serial passage is a 158 
random process unrelated to the achievement of a particular final sequence. Furthermore, the un-159 
relatedness of determined vaccine 1 and 2 sequences strongly suggests mutation patterns to be 160 
unique to each vaccine and thus the vaccine markers identified can be used with confidence to 161 




[1] Cook JKA, Ellis MM, Dolby CA, Holmes, Harvey C.Finney PM, Huggins MB. A live 166 
attenuated turkey rhinotracheitis virus vaccine. 1. Stability of the attenuated strain. Avian 167 
Pathol 1989;18:511–22. doi:10.1080/03079458908418623. 168 
[2] Williams RA, Savage CE, Jones RC. Development Of A Live Attenuated Vaccine Against 169 
Turkey Rhinotracheitis. Avian Pathol 1991;20:45–55. doi:10.1080/03079459108418740. 170 
[3] Catelli E, Naylor CJ, Ricchizzi E, Cecchinato M, Lupini C, Brown P. Field avian 171 
Metapneumovirus evolution avoiding vaccine induced immunity. Vaccine 2009;28:916–21. 172 
doi:10.1016/j.vaccine.2009.10.149. 173 
[4] Catelli E, Cecchinato M, Savage CE, Jones RC, Naylor CJ. Demonstration of loss of 174 
attenuation and extended field persistence of a live avian metapneumovirus vaccine. Vaccine 175 
2006;24:6476–82. doi:10.1016/j.vaccine.2006.06.076. 176 
[5] Lupini C, Cecchinato M, Ricchizzi E, Naylor CJ, Catelli E. A turkey rhinotracheitis outbreak 177 
caused by the environmental spread of a vaccine-derived avian metapneumovirus. Avian 178 
Pathol 2011;40:525–30. doi:10.1080/03079457.2011.607428. 179 
[6] Listorti V, Laconi A, Catelli E, Cecchinato M, Lupini C, Naylor CJ. Identification of IBV 180 
QX vaccine markers: Should vaccine acceptance by authorities require similar identifications 181 
for all live IBV vaccines? Vaccine 2017;35. doi:10.1016/j.vaccine.2017.06.021. 182 
[7] Cecchinato M, Catelli E, Lupini C, Ricchizzi E, Prosperi S, Naylor CJ. Reversion to 183 
virulence of a subtype B avian metapneumovirus vaccine: Is it time for regulators to require 184 
availability of vaccine progenitors? Vaccine 2014;32:4660–4. 185 
doi:10.1016/j.vaccine.2014.06.030. 186 
[8] Jones RC, Baxter-Jones C, Wilding GP, Kelly DF. Demonstration of a candidate virus for 187 
turkey rhinotracheitis in experimentally inoculated turkeys. Vet Rec 1986;119:599 LP-600. 188 
doi:10.1136/vr.119.24.599. 189 
[9] Wilding GP, Baxter-Jones C, Grant M. Ciliostatic agent found in rhinotracheitis. Vet Rec 190 
1986;118:735 LP-735. doi:10.1136/vr.118.26.735-b. 191 
[10] Naylor CJ, Jones RC. Demonstration of a virulent subpopulation in a prototype live 192 
attenuated turkey rhinotracheitis vaccine. Vaccine 1994;12:1225–30. doi:10.1016/0264-193 
410X(94)90248-8. 194 
[11] Naylor CJ, Ling R, Edworthy N, Savage CE, Easton AJ. Avian metapneumovirus SH gene 195 
end and G protein mutations influence the level of protection of live-vaccine candidates. J 196 
Gen Virol 2007;88:1767–75. doi:10.1099/vir.0.82755-0. 197 
[12] Brown PA, Lupini C, Catelli E, Clubbe J, Ricchizzi E, Naylor CJ. A single polymerase (L) 198 
mutation in avian metapneumovirus increased virulence and partially maintained virus 199 
viability at an elevated temperature. J Gen Virol 2011;92:346–54. doi:10.1099/vir.0.026740-200 
0. 201 
[13] Herfst S, Melero JA, Osterhaus ADME, Mas V, Fouchier RAM. Residues of the Human 202 
Metapneumovirus Fusion (F) Protein Critical for Its Strain-Related Fusion Phenotype: 203 
Implications for the Virus Replication Cycle. J Virol 2011;85:12650–61. 204 
doi:10.1128/jvi.05485-11. 205 
[14] Yun B, Guan X, Liu Y, Gao Y, Wang Y, Qi X, et al. Trypsin- and low pH-mediated 206 
fusogenicity of avian metapneumovirus fusion proteins is determined by residues at positions 207 
100, 101 and 294. Sci Rep 2015;5:15584. doi:10.1038/srep15584. 208 
 209 
 210 
Table 1: Nucleotide substitutions arising during the attenuation of #8544 to yield vaccine 1 and 211 
vaccine 2. Shading denotes the amino acid changes occurred. 212 
 213 
 #8544 Vaccine 1 Vaccine 2 
Position Gene Nucleotide Amino acid Nucleotide Amino acid Nucleotide Amino acid 
2941 UTR G NA A NA G NA 
3029 F T S T S C S 
3553 F T V C A T V 
3822 F A K A K G E 
3825 F G E A K G E 
4100 F G E G E A E 
5055 M2-1 A K G R A K 
5140 M2-1 T N C N T N 
5140 M2-2 T I C T T I 
5702 SH G C G C A Y 
5929 UTR A NA G NA A NA 
6358 G T L C L T L 
8122 L C R C R A Q 
8257 L C A C A T V 
9591 L A N A N G D 
10022 L A V G V A V 
11624 L T Y C Y T Y 
 214 
